SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001213900-19-014457
Filing Date
2019-08-02
Accepted
2019-08-02 14:15:15
Documents
51
Period of Report
2019-06-30

Document Format Files

Seq Description Document Type Size
1 10-Q rasp-20190630.htm   iXBRL 10-Q 962134
7 EXHIBITS 31.1 ex311_1.htm EX-31.1 16227
8 EXHIBITS 31.2 ex312_2.htm EX-31.2 11900
9 EXHIBITS 32.1 ex321_3.htm EX-32.1 4757
10 EXHIBITS 32.2 ex322_4.htm EX-32.2 4288
  Complete submission text file 0001213900-19-014457.txt   5020109

Data Files

Seq Description Document Type Size
2 SCHEMA rasp-20190630.xsd EX-101.SCH 54249
3 CALCULATION rasp-20190630_cal.xml EX-101.CAL 35646
4 DEFINITION rasp-20190630_def.xml EX-101.DEF 251783
5 LABEL rasp-20190630_lab.xml EX-101.LAB 854212
6 PRESENTATION rasp-20190630_pre.xml EX-101.PRE 425727
11 EXTRACTED XBRL INSTANCE DOCUMENT rasp-20190630_htm.xml XML 585621
Mailing Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170
Business Address 420 LEXINGTON AVENUE SUITE 2525 NEW YORK NY 10170 646-396-4087
Rasna Therapeutics Inc. (Filer) CIK: 0001582249 (see all company filings)

IRS No.: 392080103 | State of Incorp.: NV | Fiscal Year End: 0930
Type: 10-Q | Act: 34 | File No.: 333-191083 | Film No.: 19995439
SIC: 2834 Pharmaceutical Preparations